Your browser doesn't support javascript.
loading
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Ramalingam, Suresh S; Pérol, Maurice; Reck, Martin; Kowalyszyn, Ruben Dario; Gautschi, Oliver; Kimmich, Martin; Cho, Eun Kyung; Czyzewicz, Grzegorz; Grigorescu, Alexandru; Karaseva, Nina; Dakhil, Shaker; Lee, Pablo; Zimmerman, Annamaria; Sashegyi, Andreas; Alexandris, Ekaterine; Carter, Gebra Cuyun; Winfree, Katherine B; Garon, Edward B.
Afiliação
  • Ramalingam SS; Emory University School of Medicine, Winship Cancer Institute of Emory University, Clifton Campus, Atlanta, GA. Electronic address: ssramal@emory.edu.
  • Pérol M; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
  • Reck M; LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Wöhrendamm, Grosshansdorf, Germany.
  • Kowalyszyn RD; Centro de Investigaciones Clínicas, Instituto Multidisciplinario de Oncología, Clínica Viedma, Río Negro, Argentina.
  • Gautschi O; Luzemer Kantonsspital, Luzern, Switzerland.
  • Kimmich M; Klinik Schillerhöhe, Gerlingen, Germany.
  • Cho EK; Hematology-Oncology Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
  • Czyzewicz G; Department of Chemotherapy, John Paul II Hospital, Krakow, Poland.
  • Grigorescu A; Department of Medical Oncology, Institute of Oncology, Bucharest, Romania.
  • Karaseva N; City Clinical Oncology Dispensary, St Petersburg, Russian Federation.
  • Dakhil S; Cancer Center of Kansas, Wichita, KS.
  • Lee P; Eli Lilly and Company, Indianapolis, IN.
  • Zimmerman A; Eli Lilly and Company, Indianapolis, IN.
  • Sashegyi A; Eli Lilly and Company, Indianapolis, IN.
  • Alexandris E; Eli Lilly and Company, Indianapolis, IN.
  • Carter GC; Eli Lilly and Company, Indianapolis, IN.
  • Winfree KB; Eli Lilly and Company, Indianapolis, IN.
  • Garon EB; David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, CA.
Clin Lung Cancer ; 19(3): 270-279.e3, 2018 05.
Article em En | MEDLINE | ID: mdl-29373274
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article